•  
  •  
  •  
  •  

2025-12-13 13:13:44

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • KEC International wins New Orders of Rs. 1,150 crores
  • Emagia Convenes Global Summit to Explore the Next Wave of AI in Enterprise Finance
  • Lemon Tree Hotels signs a new property in Punjab
  • L T Elevator Ltd approves purchase of Commercial Land
  • Hindustan Zinc saves over 1 lakh GJ of energy in FY25; enough to power nearly 19,000 households annually

Keywords Selected:  LifeSciences

IPO News

  • Shilpa Pharma Lifesciences Ltd to file for IPO

Stock Report

  • Granules Life Sciences Pvt Ltd facility receives EIR from USFDA
  • Eiko LifeSciences Ltd to acquire 51% stake in SSM Formulations Pvt Ltd
  • Suven Life Sciences achieved 100% Patient Enrolment Milestone in Phase-2b Clinical Trial of Ropanicant for Major Depressive Disorder
  • Zydus launches biosimilar Denosumab 120 mg SC - protecting bone health in cancer patients
  • Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
  • Zydus receives EIR for the injectable facility located at Jarod
  • Innoxel Lifesciences Successfully Completes EU GMP Inspection by Belgium's FAMHP
  • Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg
  • Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
  • Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
  • Eris Lifesciences to consolidate its stake in Swiss Parenterals
  • SeQuent Scientific and Viyash Lifesciences Receive NCLT Approval for Transformational Merger
  • Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial
  • Closure of USFDA inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
  • Zydus' Amplitude receives CE mark for its robotic surgical system 'Andy'
  • Zydus receives approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Budesonide delayedrelease capsules, 4 mg
  • Eiko Lifesciences Ltd Q2FY26 consolidated PAT increases to Rs. 1.07 crore
  • Sai Life Sciences set to double Process R&D capacity with new facility in Hyderabad
  • Zydus receives approval from Health Canada for Mesalamine suppositories
  • Advagen Holdings Inc. to acquire stake in GEn1E Lifesciences Inc.
  • RPG Life Sciences Ltd Q2 FY2026 PAT surges to Rs. 36.85 crores

Latest Post

  • KEC International wins New Orders of Rs. 1,150 crores
  • Emagia Convenes Global Summit to Explore the Next Wave of AI in Enterprise Finance
  • Lemon Tree Hotels signs a new property in Punjab
  • L T Elevator Ltd approves purchase of Commercial Land
  • Hindustan Zinc saves over 1 lakh GJ of energy in FY25; enough to power nearly 19,000 households annually


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024